In a dispute involving band NewJeans, the government said celebrities were not entitled to the same rights as workers. Some observers say we should not be too quick to dismiss Pyongyang's military ...

Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you. Daily news – Get the most important news from ...

In 2014, Angelina Jolie took the lead on the famed fantasy film Maleficent.The villainous role she brought to life became an iconic part of pop culture, first introduced in the animated version of ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs Ozempic and Wegovy. Novo Nordisk, the manufacturer of both, recently ...

LONDON, Nov 7 — Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation ...

Hello and welcome to the details of Novo Nordisk says its experimental drug CagriSema has similar side effects to Wegovy and now with the details Nevin Al Sukari - Sana'a - Novo Nordisk said the side ...

(Bloomberg) -- Novo Nordisk A/S posted surging sales of its blockbuster weight-loss treatment Wegovy, reassuring investors after rival Eli Lilly & Co. reported disappointing sales of its obesity ...

Wegovy Q3 sales total $2.5 bln Beat forecast but group sales weaker than expected Results soothe investor worries over slowing obesity drug demand Shares rose nearly 9%, but later reversed course ...

LONDON, Nov 6 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the ...

COPENHAGEN (Reuters) - Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it ...

Novo Nordisk’s third-quarter sales growth was slightly below our expectations, but we’re maintaining our DKK 600/$86 fair value estimates, as management’s narrowed full-year 2024 guidance ...